SF3A2

Across TCGA pan-cancer cohorts, SF3A2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SF3A2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SF3A2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SF3A2 is over-expressed in tumor.

COAD, KIRC, and LIHC are the cancer types where SF3A2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SF3A2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.968	<.001	11	view →
KIRC	Female	All	+0.945	<.001	11	view →
LIHC	Female	III,IV	+1.706	<.001	9	view →
STAD	Male	II,III,IV	+1.152	<.001	9	view →
KIRP	Male	III,IV	+1.043	<.001	9	view →
HNSC	Male	All	+0.894	<.001	9	view →
LUSC	All	II,III,IV	+0.888	<.001	8	view →
BLCA	All	All	+0.679	<.001	8	view →
CHOL	Male	All	+2.643	<.001	5	view →
READ	Female	All	+0.726	<.001	5	view →
ESCA	All	All	+1.211	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SF3A2–COAD

Open the COAD breakdown →